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Is unselected genetic testing of all women with breast cancer (BC) cost-effective compared to clinical-
criteria or family-history based testing? 
 
Findings 
Unselected BRCA1/BRCA2/PALB2 testing at BC diagnosis is extremely cost-effective compared with 
clinical-criteria or family-history based BRCA1/BRCA2 testing for UK and US health systems, with 
incremental cost-effectiveness ratios of £10,470/QALY (UK) or $58,702/QALY (US) respectively. 
One year’s unselected panel-genetic testing could prevent 1,776 BC/ovarian- cancer (OC) cases and 
557 deaths in the UK; and 8,258 BC/OC-cases and 2,143 deaths in the US. 
 
Meaning  




Multigene testing for all US and UK breast cancer patients is cost-effective, suggesting this should be 







Importance: Moving to multigene testing for ‘all’ women with breast cancer (BC) could identify many 
more mutation carriers who can benefit from precision prevention. However, cost-effectiveness of this 
approach remains unaddressed. 
Objectives: To estimate incremental lifetime-effects, costs, and cost-effectiveness of multigene-testing 
all BC-patients compared with current practice of family-history/clinical-criteria based genetic (BRCA)-
testing.  
Design: Cost-effectiveness microsimulation modelling study comparing lifetime costs-&-effects of 
high-risk BRCA1/BRCA2/PALB2 (multigene) testing all unselected BC-cases (Strategy-A) with family-
history/clinical-criteria based BRCA1/BRCA2-testing (Strategy-B) in both UK-&-US populations. The 
time-horizon is lifetime and both payer and societal perspectives are presented. Probabilistic and one-
way sensitivity-analyses evaluate model uncertainty.  
Setting: Population of UK-&-US women with BC and their relatives 
Participants: Data obtained from 11,836 population-based BC-patients (regardless of family-history) 
recruited to four large research studies in the UK (Predicting-Risk-of-Breast-Cancer-at-Screening 
(PROCAS: 1389 out of 57,000 women) & Prospective-Outcomes-in-Sporadic-versus-Hereditary-
breast-cancer (POSH:2885) studies); US (Kaiser-Permanente Washington Breast-Cancer-Surveillance-
Consortium (BCSC) registry: 5892 out of 132,139 women) and Australia (Population-based BC-cases 
of the Australian-Breast-Cancer-Family-Study (ABCFS:1670 women)). 
Interventions: Strategy-A: All BC-women undergo BRCA1/BRCA2/PALB2 testing. Strategy-B: Only 
BC-women fulfilling family-history/clinical-criteria (10% BRCA-probability) undergo BRCA-testing. 
Affected BRCA/PALB2-carriers can undertake contralateral preventive-mastectomy. BRCA-carriers can 
choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation-carriers undergo cascade-
testing. Unaffected relative-carriers can undergo MRI/mammography, chemoprevention or risk-
reducing-mastectomy for BC-risk and RRSO for ovarian-cancer (OC)-risk. 
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Main Outcomes & Measures: Incremental-cost-effectiveness-ratio (ICER): incremental-cost per 
quality-adjusted-life-year (QALY) gained, is compared to standard £30,000/QALY(UK) and 
$100,000/QALY(US) thresholds. OC-incidence, BC-incidence, excess heart-disease deaths and overall 
population-impact are estimated. 
Results: Compared with current clinical-criteria/family-history-based BRCA-testing, 
(BRCA1/BRCA2/PALB2) multigene-testing for all BC-patients would cost £10,464/QALY (payer-
perspective) or £7,216/QALY (societal-perspective) in UK or $65,661/QALY (payer-perspective) or 
$61,618/QALY (societal-perspective) in US women, well below UK/NICE and US cost-effectiveness 
thresholds. Probabilistic sensitivity-analysis shows unselected multigene-testing remains cost-effective 
for 98-99% UK/ 64-68% US health-system simulations. One year’s unselected multi-gene testing could 
prevent 2,101 BC/OC-cases and 633 deaths in the UK; and 9,733 BC/OC-cases and 2,406 deaths in the 
US. Correspondingly, 8 UK/35 US excess heart-disease deaths occur annually. 
Conclusions: Unselected high-risk multigene-testing for all BC-patients is extremely cost-effective 
compared with family-history/clinical-criteria testing for UK and US health-systems. This supports 





Current national and international guidelines recommend genetic-testing in women with breast-cancer 
(BC) who fulfil recognised/established family-history(FH) or clinical-criteria. These criteria are 
surrogates for BRCA-probability with genetic-testing usually offered at around a 10% BRCA-carrier 
probability threshold.1,2 BRCA (mutation) carrier refers to an individual carrying an inheritable genetic 
Pathogenic-Variant (here-forth called ‘path-var’) which predisposes to development of BRCA-
associated cancers. However, BC-patients with genetic path-vars don’t always have a positive-FH and 
these criteria miss a large proportion (~50%) of path-var carriers.3-5 Clinical-criteria/FH-based strategy 
is dependent on patient and their doctor’s awareness of and understanding the importance of FH, FH 
accuracy, communication within/between families, and timely referrals to clinical-genetics. Limited 
health-professional/public awareness, complexity of the current structure, restricted genetic-counselling 
services and current testing pathway(s) has fostered restricted access and massive under-utilisation of 
genetic-testing services.6-8 Only 20%-30% of patients eligible get referred and access testing, and 97% 
estimated-carriers in the population remain unidentified,7 missing huge opportunities for precision-
prevention.6 Testing all BC-patients at diagnosis can increase testing access/uptake and identify many 
more path-var carriers for screening/prevention. We evaluate the cost-effectiveness of this alternative 
approach of genetic-testing all BC-patients regardless of FH. 
Knowing a patient’s genetic path-var status is important for BC management/prognosis. After 
unilateral-BC, path-var carriers can choose contralateral-prophylactic-mastectomy (CPM) to reduce 
their risk of developing contralateral-BC and opt for surgical prevention for ovarian-cancer (OC). 
Cancer affected carriers may become eligible for novel drugs (like poly-adenosine-diphosphate-ribose-
polymerase (PARP) inhibitors) and other precision-medicine based therapeutics through clinical trials.9 
A major advantage of genetic-testing is enabling testing relatives of BC path-var carriers, to identify 
unaffected relatives carrying path-vars for early diagnosis and cancer prevention. BRCA1/BRCA2 
carriers have a 17-44% risk of developing OC and 69-72% risk of BC up-to age 80-years.10 PALB2 is 
a recently established high-penetrance BC-gene, associated with a 44% BC-risk.11 There are a number 
of risk management options for unaffected relatives with path-vars. To reduce OC-risk BRCA1/BRCA2 
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path-var carriers can undergo risk-reducing salpingo-oophorectomy (RRSO).12,13 To reduce BC-risk, 
BRCA1/BRCA2/PALB2 path-var carriers can be offered enhanced MRI/mammography screening14,15, 
risk-reducing-mastectomy (RRM)16, or chemoprevention with selective-estrogen-receptor-
modulators.17  
Restricting testing to FH/clinical-criteria currently misses huge opportunities to prevent BC/OC-cases 
in unaffected individuals. In this study, we have obtained data from four large BC clinical-
trials/research-cohorts in the US, UK and Australia. We used modelling to predict downstream health-
impacts and costs and explore the cost-effectiveness of multi-gene BRCA1/BRCA2/PALB2 testing for 
‘all’ BC-cases compared to current clinical-criteria/FH-based BRCA-testing alone. We restrict this to 
BRCA1/BRCA2/PALB2 keeping in mind the principles of the ACCE-framework (analytic-validity, 
clinical-validity, clinical-utility and associated ethical/legal/social implications)18, advocated for 
clinical applicability of genetic-testing.18,19 
METHODS   
We obtained data on FH by age from 11,836 BC women diagnosed with invasive BC, including: (a) 
1,389 unselected BC-patients >45years identified in 57,902 women from the Predicting-Risk-of-Breast-
Cancer-Screening (PROCAS) study, a large-scale study within the Greater-Manchester UK NHS 
Breast-Screening-Programme;20 (b) 2,885 BC-patients <40years from 127 UK hospitals in Prospective-
Outcomes in Sporadic-versus Hereditary-breast-cancer (POSH) study;21 (c) 5,892 unselected 
BC >40years diagnosed in 132,139 women enrolled in the Kaiser-Permanente-Washington Breast-
Cancer-Surveillance-Consortium (BCSC) registry undergoing mammography screening from 1996-to-
2014;22 (d) 1,670 BC-patients both under and  over 40-years randomly selected from the unselected 
population-based BC-cases from the Australian-Breast-Cancer-Family-Study (ABCFS).23 The 
proportion of cases fulfilling FH/clinical-criteria for testing based on a ≥10% BRCA1/BRCA2 
probability-threshold was estimated using standard models e.g. BOADICEA (UK/Australian 
data)/BRCAPRO (US data).24,25 We thus obtained the proportion fulfilling FH/Clinical-criteria (FH-
positive) for BRCA-testing by age-group among unselected BC-cases in each setting (e-Table-1). The 
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ethnicity of women in these cohorts is predominantly white and representative of a Western population 
(details in e-Table-1). We obtained population-based BC incidence data by age from Cancer-Research-
UK 201526 for the UK-analysis and from US Cancer-Statistics 201527 for the US-analysis. Then we 
estimated the total number of FH-positive BC-cases based on the number of new invasive BC-cases by 
age-group in the UK-&-US populations. 
Model and genetic-testing strategy 
We developed an individual-level microsimulation model (illustrated and described in Figure-1a,1b) 
(TreeAge-Pro 2018 Williamson,MA) to analyse costs-&-effects of BRCA1/BRCA2/PALB2 testing for 
all BC-patients (Strategy-A), compared with the current practice of BRCA-testing patients using 
clinical/FH-based criteria (≥10% path-var risk) (Strategy-B). Microsimulation permits individual 
heterogeneity in gene types and ages, and can track individual patient history if the memory of events 
(e.g. risk-reducing options) impacts future cycles. The model assumes all patients in the unselected-
testing arm (Strategy-A) and only those fulfilling clinical/FH-criteria in the Criteria/FH-testing arm 
(Strategy-B) are offered genetic-counselling and testing. We assume all eligible patients undergo 
genetic-testing in our base-case analysis. If patients had a BRCA1/BRCA2/PALB2 path-var, their first-
degree relatives undergo testing for the familial path-var. If the first-degree relative had a 
BRCA1/BRCA2/PALB2 path-var, second-degree relatives are tested. We incorporate a 6.4% Variant-
of-Uncertain-Significance (VUS)-rate (BRCA1=1.23%, BRCA2=3..29%, PALB2=1.86%)28 and 8.7% 
pathogenic/likely-pathogenic re-classification rate for VUS.29 
Unaffected BRCA1/BRCA2/PALB2 path-vars carriers can choose RRM/chemoprevention to reduce 
BC-risk and RRSO (BRCA1/BRCA2 only) to reduce OC-risk, as well as undertake enhanced BC-
screening. BC-cases with path-vars can opt for CPM. Although initial studies suggested 
premenopausal RRSO is associated with reduced BC-risk,13,30,31 more recent data contradict this, 
especially in BRCA1, raising uncertainty around this issue.32 We explored no reduction in BC-risk in 
our scenario-analysis. We incorporated the excess risk and mortality from coronary-heart-disease 
(CHD) after premenopausal-oophorectomy (post-RRSO) for pre-menopausal women who don’t take 
hormone-replacement-therapy (HRT) (absolute mortality increase=3.03%).33,34 In our model, a 
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hypothetic cohort of BC-patients and their cancer-free relatives can transition to different health-
states, including no-cancer, germline ipsilateral-BC, germline contralateral-BC, sporadic-BC, 
germline-OC, sporadic-OC, and both BC-&-OC. Cancer incidence was estimated by summing the 
probabilities of pathways ending in OC or BC. The potential population-impact was calculated by 
estimating additional reduction in BC-&-OC incidence obtained through testing the entire population 
of BC-cases occurring annually in UK/US women. In line with the National-Institute-of-Health and 
Care-Excellence (NICE) economic evaluation guidelines, costs, and outcomes are discounted at 
3.5%.35 
Probabilities 
Model probabilities for the different pathways are shown in e-Table-2. The age-specific incidences of 
BC and OC among the general-population are obtained from Cancer-Research-UK 201526,36 and US 
Cancer-statistics 2015.27 The age-specific incidence of BC and OC for BRCA1/BRCA210 carriers and 
BC for PALB2 carriers,11 along-with the incidence of contralateral-BC after first BC diagnosis,10 are 
obtained from the literature.  
Relatives: number and age distribution 
We used the number of new BC-cases by age groups in UK and US to calibrate the age-distribution of 
patients in the model.26,27 The average number of first or second-degree relatives and their ages relative 
to index-cases are derived from data from the Office-for-National-Statistics (UK)37 and the National-
Centre-for-Health-Statistics (US)38 (details in e-Table-3). We used lifetables based on age and gender 
to estimate the probability of being alive for relatives at different ages, and to calculate the number of 
relatives that need to be tested and their age distribution. 
Costs 
All costs are reported at 2016 prices. The analysis was conducted from both a payer perspective and 
societal perspective. Costs included costs of genetic-testing, pre-&-post-test genetic-counselling,39,40 
costs of BC, OC and excess CHD, and costs due to productivity loss. In line with NICE 
recommendations, future healthcare costs not associated with BC, OC, or CHD were not considered.35 
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For a summary of costs and detailed explanation see e-Table-4 (medical costs) and e-Table-5 (costs 
from productivity loss).  
Life-years 
Our analysis incorporates lifetime-risks and long-term consequences providing a lifetime time-horizon. 
Female lifetables from the Office-of-National-Statistics (UK-women)41 and the National-Centre-for-
Health-Statistics (US-women)42 were used to estimate life-expectancy by 80-years for women not 
developing OC/BC. We assumed the median-age for undergoing RRM and RRSO in unaffected path-
var carriers was 37 and 40 years respectively.43 We also explored older ages of RRM (42-years) and 
RRSO (46-years) reported in a scenario analysis.44 BC and OC survival (from diagnosis to death) were 
modelled using ten-year survival-data. For details of survival estimates used see e-Table-6. 
Quality-adjusted life years (QALYs) 
QALY is a measurement of health-outcomes in economic evaluations recommended by NICE. For an 
explanation of QALY and utility-scores in the model see e-Table-7.  
Analysis 
In the microsimulation-model, for running simulations we used the number of annual new BC-cases 
(UK=54,483 and US=242,463) and corresponding female relatives (UK=215,401 and US=993,757) by 
age. Internal Validation of the model was undertaken through a process of descriptive validity, technical 
validity and face validity.45 We calculated the incremental-cost-effectiveness-ratio (ICER) by dividing 
the difference in lifetime-costs by the difference in lifetime-effects (QALYs) between the two strategies. 
ICER= (CostStrategy-A–CostStrategy-B)/(EffectStrategy-A–EffectStrategy-B). By comparing the ICER with the 
willingness-to-pay (WTP) threshold of £30,000/QALY (UK-analysis)46 and $100,000/QALY (US-
analysis)47,48, we determined whether genetically testing all BC-patients is cost-effective compared to 
clinical-criteria/FH-based testing. We undertook a number of scenario analyses, including: a) no 
reduction in BC-risk from RRSO; b) HRT compliance=nil; c) lower genetic-testing uptake rate (70%) 
in both BC patients and relatives; d) 15% BRCA1/2 path-var prevalence in BC-patients fulfilling 
clinical/FH-criteria; e) double cost of genetic-counselling (UK=£40; US=$80); f) higher median-age 
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for RRM (42-years)  and RRSO (46-years) in unaffected path-var carriers; g) the maximum values of 
cost(s) of genetic-testing at which the ICERs reach the WTP-thresholds to maintain cost-effectiveness 
of unselected multi-gene testing (Strategy-A).  
We carried out extensive one-way and probabilistic sensitivity-analyses to explore parameter 
uncertainty. In the one-way sensitivity-analysis, each parameter was varied individually to assess the 
impact on results. Probabilities and utility-scores were varied by their 95% confidence-intervals/range 
where available or by +/-10%, and costs were varied by +/-30%. In the probabilistic sensitivity-analysis, 
(PSA) all the input variables were varied simultaneously (as recommended by NICE).49 Costs were 
given a Gamma-distribution, quality-of-life a Log-normal distribution, and probability a Beta 
distribution, as suggested in the literature.50 For PSA we obtained 1,000 estimates of incremental-costs 
and effects by sampling from the distributions of each parameter. Then a cost-effectiveness 
acceptability curve was plotted to show the probability of genetically testing all BC-patients (Strategy-
A) being cost-effective at different WTP-thresholds.  
Patient and Public Involvement Statement: see e-Table-8 
RESULTS 
Compared to the current practice of clinical-criteria/FH-based genetic testing, offering unselected 
multi-gene testing for all BC-patients and subsequent predictive/cascade testing of relatives (Strategy-
A) is highly cost-effective. ICER for UK-analysis payer-perspective=£10,464/QALY (credible-
interval:£8,347/QALY,£28,965/QALY) and societal-perspective=£7,216/QALY (credible-
interval:£6,194/QALY,£23,575/QALY). The ICER for US-analysis payer-
perspective=$65,661/QALY (credible-interval:$46,613/QALY,$248,185/QALY) and societal-
perspective=$61,618 (credible-interval:$42,927/QALY,$221,781/QALY). The lifetime costs, QALYs 
and the population impact (reduced cancer incidence & deaths) for UK and US women are shown in 
Table-1. Strategy-A is associated with an additional 419-days increase in life-expectancy for UK and 
298 days for US BRCA1/BRCA2/PALB2 path-var carriers. One year’s unselected genetic-testing of all 
BC-patients can prevent an additional 1,142 BC-cases and 959 OC-cases in the UK, and 5,478 BC-
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cases and 4,255 OC-cases in the US (Table-1). This corresponds to averting 633 cancer deaths in UK 
and 2,406 cancer deaths in US populations over a lifetime-horizon (Table-1). The corresponding excess 
deaths from heart-disease are 8 in UK and 35 in US women annually.  
The one-way sensitivity-analysis (e-Figure-1a,1b,1c,1d) indicates that path-var prevalence, costs, 
utility-scores, and transition probabilities have little individual influence on the cost-effectiveness of 
unselected genetic-testing (strategy-A) from either payer/societal perspectives. Scatter plots for the UK 
and USA analyses are given in e-Figures-2a,2b,2c,2d, and show that all simulations/iterations lie in the 
north-east quadrant, indicating unselected testing is always more effective. The ICERs are lower than 
the UK/US WTP-thresholds at both the upper and lower limits of these variables. PSA (Figure-
2a,2b,2c,2d) shows that at the £30,000/QALY or $100,000/QALY thresholds, 98% (UK-payer), 99% 
(UK-societal) or 64% (US-payer), 68% (US-societal) simulations indicate that unselected genetic-
testing is cost-effective compared to FH-based/clinical-criteria testing.  
The number of unaffected female relative path-var carriers identified through cascade-testing is 1.41 in 
the UK and 1.46 in the US per index path-var carrier with BC (details in e-Table-4). Scenario-analyses 
are presented in Table-1. Unselected-testing is cost-effective from both payer-&-societal perspectives 
even with alternative scenarios of no reduction in BC-risk from RRSO (ICER-payer=£10,532/QALY 
or $66,136/QALY; ICER-societal=£7,291/QALY or $62,102/QALY); nil HRT compliance (ICER-
payer=£11,303/QALY or $89,705/QALY; ICER-societal=£7,870/QALY or $85,337/QALY); lower 
(70%) genetic-testing uptake rate in BC-patients and relatives (ICER(payer-societal)=£10,991-
£8,046/QALY or $71,006-67,285/QALY). Although the probability of being a BRCA1/BRCA2-carrier 
in those fulfilling family-history/clinical genetic-testing criteria is reported at around 10%,51,52 we also 
explored a scenario of overall 15% BRCA1/BRCA2-carrier probability. This parameter had only a 
minimal impact on ICERs: £10,585/QALY or £7,332/QALY (UK-women) and $66,694/QALY or 
$62,646/QALY (US-women). The upper limit of genetic-testing costs at which unselected genetic-
testing for all BC-patients would still remain cost-effective at the established WTP-thresholds, is 




Lower RRSO/RRM rates are reported in some populations.53 The minimum RRSO uptake-rate to 
maintain cost-effectiveness is 29% (payer-perspective) or 28% (societal-perspective) for US 
(ICER=$100,000/QALY), but unselected BC genetic-testing is cost-effective in the UK even if RRSO 
rate=nil (ICER: payer-perspective=£26,392/QALY;societal-perspective=£23,802/QALY). The 
strategy is cost-effective even if RRM-rates in unaffected relatives approach zero (UK-ICER payer-
perspective=£9,969/QALY; societal-perspective=£7,041/QALY, or US-ICER payer-
perspective=$67,235/QALY; societal-perspective=$63,643/QALY). However, if RRM-uptake=0, then 
the minimum RRSO uptake-rate to maintain cost-effectiveness at the WTP-thresholds 
(US=$100,000/QALY;UK=£30,000/QALY) is 33% (payer-perspective) or 32% (societal-perspective) 
in US health-system, and 5% (payer-perspective) or 4% (societal-perspective) in UK health-system. 
DISCUSSION 
Our analysis addresses an extremely topical and important issue of unselected multigene-testing for all 
BC-patients. We show for the first time that multigene-testing for high-penetrance BC pathogenic-
variants of well-established clinical-utility is more cost-effective and out-performs standard clinical-
criteria/FH driven BRCA-testing alone. Moving towards such a programme could lead to 1,142/959 
fewer BC/OC cases and 663 fewer BC/OC deaths in UK-women and 5,478/4,255 fewer BC/OC cases 
and 2,406 fewer BC/OC deaths in US-women annually. Our study provides QALY-based health-
outcomes which justify the cost-differences between the two strategies needed for health-care providers 
and policy makers to guide/direct resource allocation. The ICERs (UK=£10,464-£7,216/QALY and 
US=$65,661-$61,618/QALY) lie well below the established cost-effectiveness thresholds for UK 
(£20,000-£30000/QALY) and US ($100,000/QALY) health-systems. Continuing with the current 
clinical-criteria based policy reflects important opportunities missed for BC/OC prevention. 
Strengths and weaknesses 
Our study has several strengths. The model incorporates unselected BC-data from large population-
based studies, up-to-date information from the Genetics-Cancer-Prediction-through-Population-
Screening (GCaPPS) study,54 published literature, and public databases like Office-for-National-
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Statistics (UK),37,41 National-Centre-for-Health-Statistics (US),38,42 and Cancer-Research UK.26,36 We 
use the current standard of clinical-care (clinical-criteria/FH-based approach) as the comparator and 
present analyses from both payer-&-societal perspectives. Our analysis follows NICE 
recommendations: QALYs to measure health-outcomes; cost-effectiveness analysis for health-
economic evaluation;49 integration of utility-scores; discounting costs and outcomes (rate=3.5%); long 
enough horizon (lifetime) to uncover important differences in costs/outcomes; extensive/thorough one-
way and probabilistic sensitivity-analyses which support robustness/accuracy of results (e-Figures-
1a,1b,1c,1d Figures-2a,2b,2c,2d). We include a detriment for CHD mortality.33 Our costs include 
genetic-testing, VUS-management, pre- & post-test genetic-counselling, HRT-use and osteo-protection.  
Our study has limitations related to modelling assumptions. Our baseline model assumes all BC-women 
and unaffected relatives undergo genetic-testing. While very-high (up-to 98%) genetic-testing rates are 
reported in unselected genetic-testing at OC-diagnosis, corresponding genetic-testing uptake data in 
unselected BC-patients are not well-established. Our scenario analysis re-confirms cost-effectiveness 
at lower (70%) uptake rates. Although, keeping with many initial analyses13,30,55,56 our base-model 
incorporates reduction in BC-risk with pre-menopausal oophorectomy, there is recent uncertainty 
around this.32 Our scenario analysis reconfirms cost-effectiveness even without this benefit. While, 
genetic-testing costs have fallen drastically, some providers’ charge higher than our base-case 
assumption. Nevertheless, unselected BC-testing would remain cost-effective even at £1,626-£1,868 or 
$2,432-$2,679 in the UK and US respectively, which is many-fold higher than costs charged by most 
providers today. Another limitation is that our model incorporates data predominantly from 
Caucasian/White women, which can limit interpreting generalisability to non-White populations. 
While we have incorporated disutility for RRSO and RRM, surgical prevention might have associated 
complications (RRSO ~3-4%,57 RRM ~21%),58,59 which need to be factored into the informed-consent 
and decision-making process. Although premenopausal RRSO is not associated with worsening general 
quality-of-life, poorer sexual-function is reported (despite HRT).60-63 This is compensated by extremely 
high satisfaction-rates and reduction in perceived cancer-risk/worry with RRSO.60,61 RRM is negatively 
associated with sexual-pleasure/body-image. These disadvantages may be offset by reduced anxiety, 
15 
 
improved social activity,64 good cosmetic satisfaction-rates,65-68 and lack of negative impact on sexual-
activity/habit/discomfort,64 anxiety/depression or generic quality-of-life.64,66,69 We confirmed that 
unselected multigene-testing remains cost-effective at recently reported older ages of RRM/RRSO.44 
The surgical prevention (RRM/RRSO) rates used are based on established UK/US-data.43,70 However, 
these rates can vary with lower rates reported in some populations.53 Those ascertained from population-
testing may have lower BC-risks, resulting in lower uptake particularly in the absence of BC death and 
heavy cancer burden in the family. Our scenario-analyses show that unselected testing remains cost-
effective at lower RRSO and RRM rates.  
Comparison with other studies 
While earlier studies have reported cost-effectiveness of BRCA-testing at the 10% pre-test probability 
threshold,71 we report cost-effectiveness of unselected BRCA/PALB2-testing irrespective of apriori 
mutation-probability. Our findings are in line with a recent small Norwegian study (535 patients) 
showing cost-effectiveness of BRCA-testing all BC-patients.5 Our study is both broader in scope and 
draws on a much larger sample-size of population-based UK/US/Australian BC-patients. Testing at 
cancer diagnosis has now moved towards multi-gene testing. PALB2 is associated with non-syndromic 
quasi-Mendelian BC-susceptibility (BC-risk=44%) for which MRI-screening/RRM is now offered to 
path-vars. Other high-risk genes are either identifiable as pleiotropic syndromic (STK11, PTEN, p53) 
or associated with only with a small subset (lobular) and all are very rare.19 Additionally reliable risk 
estimates corrected for ascertainment bias are lacking.19 Although ATM and CHEK2 are included in 
some commercial panels, clinical-testing for these genes is not routine in most centres. Risks conferred 
by these path-vars are lower (RR~1.5-2), and while NCCN guidelines support breast-screening, RRM 
is not routinely offered, FH needs incorporation into risk-assessment/management, and many clinicians 
feel they fall below the clinical intervention threshold.19 Hence, we incorporated PALB2 along-with 




The current healthcare model of clinical-criteria/FH-based testing has numerous limitations. It misses 
a large proportion of path-var carriers who fall below the current clinical-threshold.3-5 The current 
system is plagued by massive under-utilisation of genetic-testing and missed opportunities for BC/OC 
screening and prevention.6,7 Moving towards unselected BC-testing can give an impetus for prevention 
in unaffected family members along-with clinical implications for the BC-patient. Newly diagnosed 
BC path-var carriers can opt for bilateral-mastectomy rather than breast conservation at initial BC 
surgery. This reduces contralateral BC-risk, may provide better options for breast reconstruction and 
also obviate the need for adjuvant radiotherapy.72 They also become eligible for therapeutic options like 
PARP-inhibitors. Addressing the increasing burden of long-term chronic-disease including cancer is 
one of the world’s greatest public-health challenges and important for its future viability.73 The Milken-
Institute estimates improving prevention can cut millions of chronic-disease cases and reduce treatment 
costs by billions.74 The applicability of genomics to medicine is growing and expanding. Moving 
towards unselected multi-gene testing for BC-patients can provide a huge stimulus for precision-
prevention. 
Existing genetic-counselling services running through high-risk cancer-genetics clinics don’t have the 
resources or manpower to deliver unselected genetic-testing for all BC-patients, given the large 
numbers diagnosed annually. Hence, newer ‘context specific’ delivery models will be needed for 
implementing this approach. This may require pre-test counselling to be undertaken by non-genetic 
clinicians who will need to be trained for this. This approach of ‘mainstreaming’ genetic-counselling & 
testing has recently been successfully implemented in OC-treatment pathways.75,76 Oncologists, 
surgeons and clinical nurse-specialists have provided pre-test counselling and genetic-testing,75,76 with 
genetic-services focusing on post-test counselling and support for women carrying pathogenic-variants. 
A similar approach could work for BC-patients too. Examples of other delivery options include a 
genetics-service coordinated nurse-led model,77 a Genetics-Embedded-Model (genetics 
clinician/counsellor embedded in the cancer clinic)78,79 and Telephone-counselling40,80,81 or Tele-
genetics services82 for genetic-counselling and testing.  
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Going forward, most clinicians practicing medicine will need an increased understanding of genetics 
and ability to counsel patients about this.8,83 As the volume of testing rises, the number of mutations 
and VUS being diagnosed along-with need for correct interpretation and management will increase. 
Implementation will need to be accompanied by a process of training and education for relevant 
clinicians/health professionals involved in the care pathway so that they can understand the implications 
for management including that of VUS. This is critical to ensure best evidence based care84 and avoid 
unintended/inappropriate management such as downstream predictive-testing/screening/prevention in 
VUS-cases.85 Updated guidelines need to reflect the importance of this. Appropriate clinical decision-
support tools can facilitate this transformation. Another potential bottleneck to address is laboratory 
infrastructure to manage increased sample throughput. While some health-systems have adequate 
capacity, others may lack this. Future research needs to evaluate impact and downstream outcomes of 
various context specific genetic-testing implementation and management pathways for BC-patients. 
Conclusion 
Unselected multi-gene testing for BC-susceptibility genes BRCA1/BRCA2/PALB2 can substantially 
reduce future BC-&-OC cases and deaths compared with the current clinical-strategy. Our analysis 
suggests that an unselected-testing strategy is extremely cost-effective for both UK and US health-
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Table 1. Lifetime discounted costs and effects per woman, ICER and Lifetime population impact of genetic testing for all breast cancer patients 
 Testing all BC patients Testing based on family history ICER 
 Health effects Costs Health effects Costs Cost/LYG Cost/QALY 
 LYGs QALYs Payer Societal LYGs QALYs Payer Societal Payer Societal Payer Societal 
Baseline 
UK 18.772 17.941 £7,213 £11,147 18.755 17.922 £7,016 £11,011 £11,817 £8,149 £10,464 £7,216 
US 18.652 17.813 $32,721 $36,561 18.639 17.798 $31,724 $35,625 $82,789 $77,691 $65,661 $61,618 
Scenario: No reduction in breast cancer risk from RRSO (p15=1) 
UK 18.772 17.941 £7,214 £11,148 18.755 17.922 £7,016 £11,011 £11,846 £8,201 £10,532 £7,291 
US 18.652 17.813 $32,724 $36,564 18.639 17.798 $31,724 $35,625 $82,902 $77,844 $66,136 $62,102 
Scenario: HRT compliance is nil (p21=0) 
UK 18.771 17.940 $7,218 $11,152 18.755 17.922 £7,016 £11,011 £12,706 £8,846 £11,303 £7,870 
US 18.651 17.812 $33,013 $36,852 18.639 17.798 $31,751 $35,652 $113,342 $107,823 $89,705 $85,337 
Scenario: Lower uptake rate of genetic testing in patients and relatives (70%) 
UK 18.766 17.934 £7,132 £11,096 18.755 17.922 £7,009 £11,007 £11,363 £8,319 £10,991 £8,046 
US 18.644 17.804 $32,299 $36,170 18.637 17.796 $31,691 $35,595 $80,043 $75,849 $71,006 $67,285 
Scenario: 15% probability of being a BRCA carrier in FH-positive patients (p4=0.15) 
UK 18.771 17.941 £7,213 £11,147 18.755 17.923 £7,022 £11,015 £11,973 £8,293 £10,585 £7,332 
US 18.653 17.814 $32,723 $36,563 18.641 17.800 $31,759 $35,657 $84,453 $79,326 $66,694 $62,646 
Scenario: Double cost of counselling (UK=£40 and US=$80) 
UK 18.772 17.941 £7,220 £11,154 18.755 17.922 £7,016 £11,011 £12,189 £8,521 £10,794 £7,546 
US 18.652 17.813 $32,734 $36,574 18.639 17.798 $31,725 $35,625 $83,798 $78,701 $66,462 $62,419 
Scenario: Ages for RRM and RRSO in unaffected path var carriers are 42 and 46 respectively 
22 
 
UK 18.770 17.938 $7,216 $11,165 18.755 17.922 £7,016 £11,013 £13,181 £10,043 £12,214 £9,306 
US 18.650 17.811 $32,722 $36,578 18.639 17.798 $31,720 $35,622 $92,304 $88,063 $77,715 $74,144 
IMPACT  Testing all BC 
patients 
Testing based on family 
history 
Differences    
 Patients Relatives Patients Relatives Patients Relatives Total    
UK estimates           
Germline BC cases 364* 1965 684* 2787 320* 822 1142    
Germline OC cases 447 1882 871 2417 424 535 959    
Germline BC/OC deaths 451 988 748 1325 296 337 633    
US estimates           
Germline BC cases 1639* 8727 3230* 12614 1591* 3887 5478    
Germline OC cases 2087 8655 3916 11081 1829 2426 4255    
Germline BC/OC deaths 1555 4168 2621 5508 1066 1340 2406    
           
 
ICER – incremental cost-effectiveness ratio, LYG – life years gained, QALY – quality-adjusted life year; Discounted at 3.5% 





Figure 1a,1b. Model Structure 
 
BC, breast cancer; CPM, contralateral prophylactic mastectomy; FH, family history; OC, ovarian 
cancer; RRM, risk-reducing mastectomy; RRSO, risk-reducing salpingo-oophorectomy; path var- 
pathogenic variant 
 
Figure-1 is a schematic diagram showing the microsimulation model structure for unselected and 
clinical-criteria/family-history (FH) based panel genetic testing for breast cancer (BC) patients and 
their relatives.  
Figure 1a provides a schema of the model with respect to BC patients 
Figure 1b provides a schema of the model with respect to unaffected relatives identified through 
cascade testing 
Progression through the model is dependent on the probabilities provided in Table 2.  
 
Figure-1a: 
Patients in unselected testing arm:  
In the unselected testing arm, all breast cancer (BC) patients are offered genetic testing and get 
classified as path var carriers, VUS, or non-carriers. A proportion (8.7%) of patients with VUS results 
will subsequently get reclassified as path var carriers.  
BRCA1/BRCA2 BC path var carriers identified are offered options of contralateral prophylactic 
mastectomy (CPM) and risk-reducing salpingo-oophorectomy (RRSO), and PALB2 BC path var 
carriers identified are offered CPM. Depending on the probability of patients undertaking a CPM 
and/or RRSO they may progress to either germline contralateral BC or both BC and OC. Also they 
have a probability of dying from germline breast cancer. Patients who do not progress or die would 
stay in the state of germline ipsilateral BC and undertake the next cycle. 
BRCA1/BRCA2/PALB2 negative patients have sporadic BC. Age-dependent probabilities allow them 
to develop sporadic OC and progress to the health state of ‘BC and OC’. They also have a probability 
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of dying from sporadic BC. Women who do not progress to BC and OC or die would stay in the 
health state of sporadic BC to undertake the next cycle. 
Patients in clinical criteria/FH testing arm 
In the clinical criteria/FH testing arm, patients with positive FH (fulfilling clinical criteria) undergo 
genetic testing and are classified as path var carriers, VUS, or non-carriers. A proportion of patients 
with VUS results will subsequently get reclassified as path var carriers.  
Patients with negative FH do not undertake genetic testing. They can be undetected BRCA1/BRCA2 
path var carriers, undetected PALB2 path var carriers, or BRCA1/BRCA2/PALB2 negative.  
Options of CPM/RRSO and disease progression for identified BRCA1/BRCA2/PALB2 BC path var 
carriers and disease progression for BRCA1/BRCA2/PALB2 negative BC patients, is the same as those 
in the unselected testing arm and are described above.  
Undetected BRCA1/BRCA2 path var carriers are not offered CPM or RRSO, and undetected PALB2 
path var carriers are not offered CPM. Depending on the baseline risk (no risk-reducing options) they 
progress to either germline contralateral BC or both BC and OC. Also they have a probability of 
dying from germline breast cancer. Patients who do not progress or die would stay in the state of 
germline ipsilateral BC and undertake the next cycle. 
 
Figure-1b 
Relatives in the unselected testing arm: 
In the unselected testing arm, relatives of BC path var carriers are offered BRCA1/BRCA2/PALB2 
genetic testing and classified as path var carriers or non-carriers. Relatives of BC patients with VUS 
(8.7%) who get reclassified as path var carriers are also offered predictive BRCA1/BRCA2/PALB2 
testing.  
Relatives identified with BRCA1/BRCA2 path var are offered options of risk-reducing mastectomy 
(RRM) and RRSO, and those identified with PALB2 path var are offered RRM. Unaffected relatives 
can also opt for chemoprevention for BC. Depending on the probability of path var carriers 
undertaking an RRM and/or RRSO (+/- chemoprevention) they progress to either germline BC 
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(BRCA1/BRCA2/PALB2) or germline OC (BRCA1/BRCA2), or stay in the health state of no cancer. 
They have a probability of dying from the background all-cause mortality. 
BRCA1/BRCA2/PALB2 negative women progress to sporadic BC or sporadic OC, or stay in the health 
state of no cancer. They have a probability of dying from the background all-cause mortality.  
Relatives in the clinical-criteria/FH testing arm: 
In the clinical-criteria/FH testing arm, relatives of identified BRCA1/BRCA2 mutation patients 
undergo predictive BRCA1/BRCA2 genetic testing. They are classified as path var carriers, or non-
carriers. Relatives of BC patients with VUS who get reclassified as path var carriers also undergo 
predictive BRCA1/BRCA2 testing.  
 PALB2 path var carriers cannot be detected with only FH based BRCA1/BRCA2 genetic testing being 
offered. Relatives of patients with negative FH may be undetected BRCA1/BRCA2 path var carriers, 
undetected PALB2 path var carriers, or BRCA1/BRCA2/PALB2 negative.  
The options of RRM and RRSO for identified carriers are the same as in the unselected testing arm. 
For identified BRCA1/BRCA2/PALB2 path var carriers and non-carries (BRCA1/BRCA2/PALB2 
negative), the disease progression is the same as relatives in the unselected testing arm.  
Undetected BRCA1/BRCA2 path var carriers are not offered RRM or RRSO, and undetected PALB2 
path var carriers are not offered RRM. Depending on the baseline risk they progress to either germline 
BC or germline OC, or stay in ‘no cancer’ health state. Also they have a probability of dying from the 




Figure 2. Cost-effectiveness acceptability curves (Probabilistic Sensitivity Analyses) 
Probabilistic sensitivity analysis in which all model parameters/variables are varied 
simultaneously across their distributions to further explore model uncertainty.   
X-axis: Incremental cost-effectiveness ratio (ICER) in terms of Cost ($)/QALY;  
Y-axis: Proportion of simulations.  
The results of 1000 simulations were plotted on a cost-effectiveness acceptability curve 
showing the proportion of simulations (Y-axis) that indicated that the intervention was cost-
effective at different willingness to pay thresholds (X-axis). Separate curves are plotted for 
UK, USA 
 
Figure 2a,2b. Cost-effectiveness acceptability curves – UK 
The dotted line marks the proportion of simulations found to be cost-effective at the 
willingness to pay (WTP) threshold of £30,000/QALY in the UK analysis. At the 
£30,000/QALY WTP threshold, 2% simulations are cost-effective for clinical criteria/family 
history-based testing and 98% simulations are cost-effective for unselected genetic testing 
from the payer perspective (Figure-2a); 1% simulations are cost-effective for clinical 
criteria/family history-based testing and 99% simulations are cost-effective for unselected 
genetic testing from the societal perspective (Figure 2b). 
 
Figure 2c,2d. Cost-effectiveness acceptability curves – US 
 
The dotted line marks the proportion of simulations found to be cost-effective at the 
willingness to pay threshold of $100,000/QALY in the US analysis. At the $100 000/QALY 
WTP threshold, 36% simulations are cost-effective for clinical criteria/family history-based 
testing and 64% simulations are cost-effective for unselected genetic testing from the payer 
perspective (Figure 2c); 32% simulations are cost-effective for clinical criteria/family 
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history-based testing and 68% simulations are cost-effective for unselected genetic testing 
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